Royalty Pharma plc Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Royalty Pharma plc (RPRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$8.33 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2021-11-10
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2021-09-30 was -$8.33M, a 319.06% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2021-06-30 was -$4.04M, a 175.92% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2020-09-30 was $3.80M.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2020-06-30 was $5.33M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month |
|---|---|---|---|
| 2021-09-30 | -$8.33M 10-Q · filed 2021-11-10 | -$12.37M derived: sum of 2 quarters · filed 2021-11-10 | -$17.86M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$4.04M 10-Q · filed 2021-08-11 | -$9.53M 10-Q · filed 2021-08-11 | |
| 2020-09-30 | $3.80M 10-Q · filed 2021-11-10 | $9.13M derived: sum of 2 quarters · filed 2021-11-10 | $56.25M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $5.33M 10-Q · filed 2021-08-11 | $52.44M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |